GPGI Inc (NV) earnings beat by $0.01, revenue topped estimates

GPGI Inc (NYSE: GPGI) reported Q3 EPS of $0.26, beating estimates by $0.01, with revenue of $509.6M, exceeding expectations of $471M. The stock is down 14.74% over 3 months and 39.78% over 12 months. InvestingPro rates its financial health as 'weak performance'.

Original reporting
Published Nov 5, 2026, 3:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GPGI
Bullish
medium confidence
Mentioned
$GPGI
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GPGIBullishLow
01

Why it matters

The surprise beat could prompt short‑term buying, but the company's weak financial health rating tempers expectations.

02

Market read

Micro‑cap earnings beat with limited broader market impact.

03

What to watch

Potential cash‑burn concerns and weak balance sheet may outweigh the earnings beat.

Relevance 6/10Novelty 8/10Timing: post‑market today

Background

GPGI Inc reported its third‑quarter results, showing a modest earnings and revenue beat.

Company-level read

Ticker impact

$GPGIBullishMedium confidence
Context

Q3 earnings posted EPS $0.26 beating estimate $0.25 and revenue $509.6M vs $471M estimate.

Expected impact

likely upward bias as market prices in the beat.

Evidence & confidence

Small beat on both EPS and revenue for a micro‑cap; limited float suggests price could move on the news.

Market effects

Minor impact on the broader biotech/health‑tech sector; earnings beat does not shift sector outlook.

Limited to U.S. small‑cap market; no broader regional effect.

Low global relevance.

Counterpoint

The beat may be priced in quickly, and the weak financial health rating could limit upside.

Key entities

  • GPGI Inc

    U.S. listed biotech firm (NYSE:GPGI).

Related articles

$GPGIMed

GPGI 3Q 2026: Revenue $0, EPS $0.26 — 10-Q Summary

GPGI reported 3Q 2026 revenue of $0 but net income of $76M, up 143.5% YoY, driven by equity-method investment earnings. GPGI Holdings sales rose 321.5% YoY to $509.6M, with Husky and CompoSecure contributing to growth. Adjusted EBITDA for CompoSecure and Husky combined was $150.0M, up from $49.8M YoY.

$GPGIHighAI 8/10

GPGI (GPGI) Q3 2026 Earnings Call Transcript

GPGI reported Q3 2026 earnings with sales up 5% YoY to $509.6M and EBITDA up 7% to $146.3M. The company expects low single-digit revenue growth and high single-digit EBITDA growth in Q4. Full-year 2026 guidance was adjusted, with revenue expected to meet prior forecasts but EBITDA and free cash flow lowered due to Husky's delayed cost actions and mix issues. GPGI aims for long-term growth with mid- to high single-digit annual organic growth and double-digit EBITDA growth.

$GPGILow

GPGI Third Quarter 2026 Earnings Presentation November 5, 2026 TM

GPGI, Inc. (GPGI) filed an SEC Form 8-K — Results of Operations and Financial Condition. GPGI Third Quarter 2026 Earnings Presentation November 5, 2026 TM Disclaimer 2 Caution Concerning Forward-Looking Statements: This presentation, and other statements that GPGI, Inc. (“GPGI,” “we,” “us” or the “Company”) may make in connection therewith, contains forward-looking s

$GPGIMedAI 8/10

GPGI (GPGI) Q2 2026 Earnings Call Transcript

GPGI, Inc. (GPGI) reported Q2 2026 results on an earnings call. Pro forma adjusted net sales were $473.2 million, down 4%, and pro forma adjusted EBITDA was $113.9 million, down 13%, with margin at 24.1%. GAAP net income was $50.3 million. FY2026 guidance: revenue $1.95B-$2.1B, adjusted EBITDA $550M-$610M, and free cash flow $275M-$325M.

$GPGIMed

1 News Release GPGI Reports Second Quarter 2026 Results

GPGI, Inc. (GPGI) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 News Release GPGI Reports Second Quarter 2026 Results ▪ CompoSecure delivers record ROS-enabled results ▪ Husky performance in line with expectations ▪ ROS deployment accelerating at both companies ▪ Progress across the platform – reiterating full year 2026 guidance Second Quar